-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 16, Kelun Pharmaceutical announced that Kelun Botai, a holding subsidiary of the company, licensed its biological macromolecular tumor project A with independent intellectual property rights to MSD (Merck & .
) for commercial development outside Chi.
The terms show that Merck will pay Colombo Tech the down payment, various milestone payments and corresponding net sales commissions according to the commercial development sta.
Colombo received a one-time, non-refundable payment of $17 million when the license agreement became effective and a one-time, non-refundable payment of $30 million after the signing of the amendment to this agreement, with cumulative milestone payments not exceeding $363 billion , and commission according to the proportion of net sales agreed by both parti.
Through this license out transaction, Kelun Pharmaceutical hopes to open the overseas market of Projec.
Kelun Pharmaceutical believes that the signing of this amendment to the license agreement will help the development speed of Project A in the wor.
If the application is approved and listed, it may provide new treatment options for global tumor patients, and will further enhance the internationalization of the company's innovative projec.
As of December 31, 2021, the innovation pipeline of Kelun Pharmaceuticals mainly promotes 12 clinical-stage projects, involving major diseases such as malignant tumors, liver diseases, autoimmunity, and anesthesia and analges.
In recent years, with the continuous enhancement of the "self-hematopoietic" ability of China's domestic innovative pharmaceutical companies and the continuous improvement of the quality of innovative research and development, license out transactions have gradually become comm.
Through this model, local innovative pharmaceutical companies can quickly integrate into the international market even if they do not have independent overseas sales teams, and convert their technological achievements into ca.
In March 2007, the global development rights of Chidamide, a product under development of Chipchip Biosciences outside China, were authorized to HUYA in the United States at a price of 28 million US dollars, which means the opening of the road to license-out of innovative drugs in Chi.
In September 2015, Hengrui Medicine sold the foreign rights of its PD-1 antibody drug camrelizumab to INCYTE for US$795 million, which is also the first time that a local pharmaceutical company has transferred innovative dru.
After China joined ICH in 2017, the number of innovative drug license-outs accelerat.
According to incomplete statistics, there are currently more than 50 license-out transactions in the domestic pharmaceutical industry, of which there will be more than 30 license-out transactions in 2021 alone, with a total disclosed transaction amount of approximately US$13 billi.
The licensors involve new and old local pharmaceutical companies such as Hengrui, Hansoh, Fosun, Kelun, BeiGene, Tianjing, Cinda, and Cornersto.
Judging from the license-out projects of domestic innovative drugs exceeding US$1 billion in recent years, for example, in early 2021, BeiGene announced that it had reached a cooperation and licensing agreement with Novartis on the development, production and commercialization of tislelizumab in multiple countri.
BeiGene received a down payment of up to $650 million; at the end of 2021, BeiGene announced a blockbuster deal with Novartis to license the main overseas rights of TIGIT antibody to Novartis for $9 billion; August 2021 , Rongchang Bio licensed Vidicitumumab to Seattle Gene at a price of US$6 billion, setting a new down payment amount for domestic license-out transactio.
From the perspective of the industry, license out transactions represent the innovation capabilities of domestic new dru.
With the increase in license out transactions, it means that the innovation capabilities of domestic drugs are improvi.
However, many people said that the long-term license-out-based commercialization model is also difficult to support the continuous and stable profitability of enterpris.
This model poses certain challenges to the growth of the company's market value and sustainable operatio.
) for commercial development outside Chi.
The terms show that Merck will pay Colombo Tech the down payment, various milestone payments and corresponding net sales commissions according to the commercial development sta.
Colombo received a one-time, non-refundable payment of $17 million when the license agreement became effective and a one-time, non-refundable payment of $30 million after the signing of the amendment to this agreement, with cumulative milestone payments not exceeding $363 billion , and commission according to the proportion of net sales agreed by both parti.
Through this license out transaction, Kelun Pharmaceutical hopes to open the overseas market of Projec.
Kelun Pharmaceutical believes that the signing of this amendment to the license agreement will help the development speed of Project A in the wor.
If the application is approved and listed, it may provide new treatment options for global tumor patients, and will further enhance the internationalization of the company's innovative projec.
As of December 31, 2021, the innovation pipeline of Kelun Pharmaceuticals mainly promotes 12 clinical-stage projects, involving major diseases such as malignant tumors, liver diseases, autoimmunity, and anesthesia and analges.
In recent years, with the continuous enhancement of the "self-hematopoietic" ability of China's domestic innovative pharmaceutical companies and the continuous improvement of the quality of innovative research and development, license out transactions have gradually become comm.
Through this model, local innovative pharmaceutical companies can quickly integrate into the international market even if they do not have independent overseas sales teams, and convert their technological achievements into ca.
In March 2007, the global development rights of Chidamide, a product under development of Chipchip Biosciences outside China, were authorized to HUYA in the United States at a price of 28 million US dollars, which means the opening of the road to license-out of innovative drugs in Chi.
In September 2015, Hengrui Medicine sold the foreign rights of its PD-1 antibody drug camrelizumab to INCYTE for US$795 million, which is also the first time that a local pharmaceutical company has transferred innovative dru.
After China joined ICH in 2017, the number of innovative drug license-outs accelerat.
According to incomplete statistics, there are currently more than 50 license-out transactions in the domestic pharmaceutical industry, of which there will be more than 30 license-out transactions in 2021 alone, with a total disclosed transaction amount of approximately US$13 billi.
The licensors involve new and old local pharmaceutical companies such as Hengrui, Hansoh, Fosun, Kelun, BeiGene, Tianjing, Cinda, and Cornersto.
Judging from the license-out projects of domestic innovative drugs exceeding US$1 billion in recent years, for example, in early 2021, BeiGene announced that it had reached a cooperation and licensing agreement with Novartis on the development, production and commercialization of tislelizumab in multiple countri.
BeiGene received a down payment of up to $650 million; at the end of 2021, BeiGene announced a blockbuster deal with Novartis to license the main overseas rights of TIGIT antibody to Novartis for $9 billion; August 2021 , Rongchang Bio licensed Vidicitumumab to Seattle Gene at a price of US$6 billion, setting a new down payment amount for domestic license-out transactio.
From the perspective of the industry, license out transactions represent the innovation capabilities of domestic new dru.
With the increase in license out transactions, it means that the innovation capabilities of domestic drugs are improvi.
However, many people said that the long-term license-out-based commercialization model is also difficult to support the continuous and stable profitability of enterpris.
This model poses certain challenges to the growth of the company's market value and sustainable operatio.
